Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™

Vaccine

Volumn 35, Issue 45, 2017, Pages 6208-6217

  Venkatraman, Navin ^a,b   Anagnostou, Nicholas ^a,b   Bliss, Carly ^a   Bowyer, Georgina ^a   Wright, Danny ^a   Lövgren Bengtsson, Karin ^c   Roberts, Rachel ^a,b   Poulton, Ian ^a,b   Lawrie, Alison ^a,b   Ewer, Katie ^a   V S Hill, Adrian ^a  

^a NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c NOVAVAX INC   (United States)

Author keywords

Malaria; Matrix M; Vaccine; Viral vectored

Indexed keywords

ADENOVIRUS VECTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; EPITOPE; IMMUNOGLOBULIN G; MATRIX-M; NANOPARTICLE; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; SAPONIN;

ABDOMINAL PAIN; ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; BURNING SENSATION; CELLULAR IMMUNITY; CHILL; CLINICAL ARTICLE; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; FATIGUE; FEMALE; FEVER; HEADACHE; HEART RATE; HEAT; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE CONTUSION; INSOMNIA; LEUKOPENIA; LOW BACK PAIN; MALAISE; MALARIA; MALE; MIDDLE AGED; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OBSERVATIONAL STUDY; OPEN STUDY; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RIGOR; SIDE EFFECT; SKIN REDNESS; SWELLING; SYSTEMIC DISEASE; YOUNG ADULT; ADENOVIRIDAE; ADOLESCENT; CLINICAL TRIAL; ENZYME LINKED IMMUNOSPOT ASSAY; GENE VECTOR; IMMUNOLOGY; MALARIA FALCIPARUM; PROCEDURES; SECONDARY IMMUNIZATION; T LYMPHOCYTE; VACCINATION; VACCINE IMMUNOGENICITY; VACCINIA;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES; FEMALE; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; IMMUNOGENICITY, VACCINE; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; NANOPARTICLES; PROTOZOAN PROTEINS; SAPONINS; T-LYMPHOCYTES; VACCINATION; VACCINIA; YOUNG ADULT;

EID: 85029645095     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.09.028     Document Type: Article

References (33)

1. WHO, World Malaria Report; 2013.
2. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014;11(7): e1001685.
3. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015;386(9988): 31–45.
4. RTS, S Clinical Trials Partnership, A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 367:24 (2012), 2284–2295.
5. Agnandji, S.T., et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 365:20 (2011), 1863–1875.
6. Malaria Vaccine Funders Group. Malaria Vaccine Technology Roadmap; 2013 [20/3/13]; Available from: http://www.who.int/immunization/topics/malaria/vaccine_roadmap/TRM_update_nov13.pdf?ua=1.
7. Doolan, D.L., Hoffman, S.L., The complexity of protective immunity against liver-stage malaria. J Immunol 165:3 (2000), 1453–1462.
8. Khusmith, S., Sedegah, M., Hoffman, S.L., Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect Immun 62:7 (1994), 2979–2983.
9. Romero, P., et al. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341:6240 (1989), 323–326.
10. Todryk, S.M., et al. Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS One, 3(4), 2008, e2027.
11. Malik, A., et al. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci U S A 88:8 (1991), 3300–3304.
12. Ewer, K.J., et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun, 4, 2013, 2836.
13. Ogwang, C., et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med, 7(286), 2015, 286re5.
14. O'Hara, G.A., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205:5 (2012), 772–781.
15. Afolabi, M.O., et al. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and Infants. Mol Ther 24:8 (2016), 1470–1477.
16. Bliss, C.M., et al. Viral vector malaria vaccines induce high-level T Cell and antibody responses in West African children and infants. Mol Ther 25:2 (2017), 547–559.
17. Kimani, D., et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mol Ther 22:11 (2014), 1992–2003.
18. Ogwang, C., et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One, 8(3), 2013, e57726.
19. Hodgson, S.H., et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis 211:7 (2015), 1076–1086.
20. Long, C.A., Zavala, F., Malaria vaccines and human immune responses. Curr Opin Microbiol 32 (2016), 96–102.
21. Rampling, T., et al. Safety and high level efficacy of the combination malaria vaccine REGIMEN of RTS, S/AS01B with Chimpanzee adenovirus 63 and modified vaccinia ankara vectored vaccines expressing ME-TRAP. J Infect Dis 214:5 (2016), 772–781.
22. Bigaeva, E., et al. Meta-analysis on randomized controlled trials of vaccines with QS-21 or ISCOMATRIX adjuvant: safety and tolerability. PLoS One, 11(5), 2016, e0154757.
23. Bengtsson, K.L., et al. Matrix-M adjuvant: enhancing immune responses by 'setting the stage’ for the antigen. Expert Rev Vaccines 12:8 (2013), 821–823.
24. Cox, R.J., et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine 29:45 (2011), 8049–8059.
25. Cox, R.J., et al. Matrix M H5N1 vaccine induces cross-h5 clade humoral immune responses in a randomized clinical trial and provides protection from highly pathogenic influenza challenge in Ferrets. PLoS One, 10(7), 2015, e0131652.
26. Bengtsson, K.L., et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine 34:16 (2016), 1927–1935.
27. Cox, F., et al. Matrix-M adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine. Virol J, 12, 2015, 210.
28. Bejon, P., et al. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials, 1(6), 2006, e29.
29. Hahn, T., Rapid manufacture and release of a GMP batch of Zaire ebolavirus glycoprotein vaccine made using recombinant baculovirus-Sf9 insect cell culture technology. BioProcess J, 14(1), 2015, 6.
30. Sheehy, S.H., et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One, 7(2), 2012, e31208.
31. de Barra, E., et al. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS One, 9(12), 2014, e115161.
32. Sheehy, S.H., et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19:12 (2011), 2269–2276.
33. Lalvani, A., et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS, S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 180:5 (1999), 1656–1664.